PMID- 7871405
OWN - NLM
STAT- MEDLINE
DCOM- 19950330
LR  - 20130520
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 125
IP  - 6
DP  - 1995 Feb 11
TI  - [Participation in multicenter studies as quality control in the therapy of 
      Hodgkin disease: an interim report].
PG  - 217-24
AB  - From 1988 to 1992 the Swiss Group for Clinical Cancer Research (SAKK) entered 113 
      patients with Hodgkin's disease into three stage adapted trials (HD-4-6) from the 
      German Hodgkin Study Group (DHSG). In an interim analysis freedom from treatment 
      failure (FFTF) and overall survival (OS) of the SAKK patients (SAKK-pt) were 
      compared to the remaining study population (GHSH-pt) (median follow-up: 30 months 
      for HD-4 and HD-5, 24 months for HD-6). RESULTS: HD-4: SAKK (n = 16), DHSG (n = 
      241), FFTF-SAKK: 100%, FFTF-DHSG: 85%, p: ns, OS-SAKK: 100%, OS-DHSG: 99%, p: ns, 
      HD-5: SAKK (n = 66), DHSG (n = 639), FFTF-SAKK: 90%, FFTF-DHSG: 85%, p: ns, 
      OS-SAKK: 93%, OS-DHSG: 95%, p: ns, HD-6; SAKK (n = 31), DHSG (n = 411): 
      FFTF-SAKK: 62%, FFTF-DHSG: 68%, p: ns, OS-SAKK: 70%, OS-DHSG: 88%, p < 0.008. The 
      results in the SAKK patients with advanced disease are unsatisfactory. Despite 
      the fact that the treatment was given on time with full doses, 10/30 patients 
      achieved no complete remission (CR). Only one patient relapsed after an initial 
      CR. 6 patients had primary progressive disease. 6 patients died despite 
      conventional salvage chemotherapy. High dose chemotherapy/autologous bone marrow 
      transplantation (HDC/ABMT) was only given to 3 out of 8 potential candidates. 
      Only 2/11 patients are still alive and disease-free after relapse or initial 
      progression. Both had received HDC/ABMT as part of their salvage regimen. This 
      interim analysis identifies a group of patients in which treatment strategies 
      need to be optimized.
FAU - Lohri, A
AU  - Lohri A
AD  - Schweizerische Arbeitsgruppe fur klinische Krebsforschung (SAKK), Bern.
FAU - Leyvraz, S
AU  - Leyvraz S
FAU - Cerny, T
AU  - Cerny T
FAU - Hess, U
AU  - Hess U
FAU - Honegger, H P
AU  - Honegger HP
FAU - Greiner, R
AU  - Greiner R
FAU - Castiglione, M
AU  - Castiglione M
FAU - Herrmann, R
AU  - Herrmann R
FAU - Loffler, M
AU  - Loffler M
FAU - Hasenclever, D
AU  - Hasenclever D
AU  - et al.
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Teilnahme an Multizenterstudien als Qualitatskontrolle bei der Therapie des 
      Morbus Hodgkin: ein Interimreport.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Female
MH  - Germany
MH  - Hodgkin Disease/*drug therapy
MH  - Humans
MH  - Male
MH  - Salvage Therapy
MH  - Switzerland
EDAT- 1995/02/11 00:00
MHDA- 1995/02/11 00:01
CRDT- 1995/02/11 00:00
PHST- 1995/02/11 00:00 [pubmed]
PHST- 1995/02/11 00:01 [medline]
PHST- 1995/02/11 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1995 Feb 11;125(6):217-24.